Company intelligence / Profile preview

Targinta

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

Targinta has developed TARG10, a therapeutic antibody targeting integrin α10β1, which has shown strong inhibitory effects on growth, proliferation, and migration of cancer cells, as well as reduction of tumor growth and metastasis in preclinical triple-negative breast cancer models. The company is also developing TARG9, an antibody-drug conjugate for glioblastoma.

Therapeutic areas: Oncology
Modalities: Therapeutic antibodiesAntibody-drug conjugates (ADCs)
Industry: Biotech

Drug pipeline

2 assets

TARG9

Preclinical

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Targinta.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Targinta.

Explore the full profile